drugset / Trial / NCT07024277
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
RandomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.
Timeline
- Start
- 2025-08
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZG006 | Unknown | 10 mg | Intravenous |
| Subject | ZG006 | Unknown | 30 mg | Intravenous |